Physician profile
Sapna V Thomas
NPI 1881614931
$8,970.13
in general payments reported to CMS, 2019-2025
28 companies · $2,388 in 2025
The $2,388 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $190 · 2021: $429 · 2022: $876 · 2023: $2,721 · 2024: $1,331 · 2025: $2,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,342 · Consulting Fee: $2,085 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,341.65 |
| Consulting Fee | $2,085.00 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,520.64 | 2019-2025 | Stelara, Tremfya, Simponi |
| Abbvie INC. | $1,889.12 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $641.26 | 2019-2025 | |
| Braintree Laboratories, INC. | $566.37 | 2019-2025 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $497.35 | 2019-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $322.66 | 2019-2025 | Cre Pro |
| Qol Medical, LLC | $250.32 | 2021-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $248.88 | 2024-2025 | Voquezna |
| Celgene Corporation | $204.73 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.60 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $159.70 | 2024-2025 | Omvoh |
| Allergan, INC. | $152.54 | 2019 | |
| Merck Sharp & Dohme LLC | $143.65 | 2020-2024 | Dificid, Zinplava |
| Genzyme Corporation | $122.23 | 2022-2025 | |
| Ardelyx, INC. | $120.84 | 2022-2025 | Ibsrela |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $113.59 | 2023-2025 | Vowst, Zenpep |
| Ethicon US, LLC | $105.23 | 2019 | |
| Ironwood Pharmaceuticals, INC | $98.88 | 2021-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $98.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $94.67 | 2022-2025 | Dupixent |
| Ucb, INC. | $85.35 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $83.62 | 2024-2025 | Rebyota, Clenpiq |
| Nestle Healthcare Nutrition INC. | $77.08 | 2021-2023 | |
| Celltrion USA INC. | $60.83 | 2024-2025 | Vegzelma |
| Exact Sciences Corporation | $46.32 | 2025 | Cologuard Collection Kit |
| Organon LLC | $35.03 | 2024-2025 | Renflexis, Hadlima |
| Abbott Laboratories | $17.30 | 2025 | Alinity |
| Alfasigma USA, INC. | $12.71 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sapna Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.